Do you have Behavioral Variant Frontotemporal Dementia (bvFTD or Pick's disease) or care for someone who does?
This Behavioral Variant Frontotemporal Dementia (bvFTD) clinical trial website provides information that will help you determine whether you qualify for participation in a clinical research study that is now enrolling. Find out in just a few minutes whether you prequalify for this bvFTD study.
Currently, because no treatments are available for Behavioral Variant Frontotemporal Dementia, clinical trials are necessary in order to develop new medicines for treating patients with bvFTD. Clinical trials form a valuable part of the process that may bring forward new treatments for those having been diagnosed with bvFTD.
This clinical study for bvFTD has been more than 30 years in the making. Of the potential medicines that get tested in those early stages, only about 1 in 1,000 is promising enough to be tested in humans.
The purpose of this voluntary research study is to evaluate the safety and effectiveness of LMTX™ and to determine whether it can slow the progression of the disease. If you agree to participate, you will receive at no cost:
- study-related medical tests
- investigational study drug
- attention of a medical team
It is estimated that more than 60,000 people in the United States have Behavioral Variant Frontotemporal Dementia, which accounts for about 10 to 20% of all dementia occurrences. In many cases, FTD affects those in their 40s, which is younger than the typical age seen in other dementias.
In bvFTD, the frontal and temporal lobes are affected first, which impacts behaviour and emotion.
As the disease progresses, other parts of the brain are affected, eventually producing a global dementia.
We invite you to continue reading about this important clinical research study and the steps to take to get involved.